Literature DB >> 11850250

Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.

Julia Walochnik1, Michael Duchêne, Karin Seifert, Andreas Obwaller, Thomas Hottkowitz, Gerhard Wiedermann, Hansjörg Eibl, Horst Aspöck.   

Abstract

Free-living amoebae of the genus Acanthamoeba are causing serious chronic conditions such as destructive keratitis in contact lens wearers or granulomatous amoebic encephalitis in individuals with compromised immune systems. Both are characterized by the lack of availability of sufficiently effective and uncomplicated, manageable treatments. Hexadecylphosphocholine (miltefosine) is licensed for use as a topical antineoplastic agent, but it is also active in vitro against several protozoan parasites, and it was applied very successfully for the treatment of human visceral leishmaniasis. The aim of our study was to evaluate the efficacy of hexadecylphosphocholine and other alkylphosphocholines (APCs) against Acanthamoeba spp. The in vitro activities of eight different APCs against three Acanthamoeba strains of various pathogenicities were determined. All substances showed at least amoebostatic effects, and some of them disrupted the amoebae, as shown by the release of cytoplasmic enzyme activity. Hexadecylphosphocholine exhibited the highest degree of cytotoxicity against trophozoites, resulting in complete cell death at a concentration as low as 40 microM, and also displayed significant cysticidal activity. Hexadecylphosphocholine may be a promising new candidate for the topical treatment of Acanthamoeba keratitis and, conceivably, even for the oral treatment of granulomatous amoebic encephalitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850250      PMCID: PMC127497          DOI: 10.1128/AAC.46.3.695-701.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.

Authors:  P Kaufmann-Kolle; M R Berger; C Unger; H Eibl
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

2.  Species identification and virulence of Acanthamoeba strains from human nasal mucosa.

Authors:  J F De Jonckheere; R Michel
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

3.  Treatment of acanthamoeba keratitis with chlorhexidine.

Authors:  P Kosrirukvongs; D Wanachiwanawin; G S Visvesvara
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

4.  Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient.

Authors:  C A Slater; J Z Sickel; G S Visvesvara; R C Pabico; A A Gaspari
Journal:  N Engl J Med       Date:  1994-07-14       Impact factor: 91.245

5.  Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole.

Authors:  M Seijo Martinez; G Gonzalez-Mediero; P Santiago; A Rodriguez De Lope; J Diz; C Conde; G S Visvesvara
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp.

Authors:  J Walochnik; A Obwaller; H Aspöck
Journal:  Appl Environ Microbiol       Date:  2000-10       Impact factor: 4.792

7.  Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine.

Authors:  I G Duguid; J K Dart; N Morlet; B D Allan; M Matheson; L Ficker; S Tuft
Journal:  Ophthalmology       Date:  1997-10       Impact factor: 12.079

8.  Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

Authors:  J Kötting; M R Berger; C Unger; H Eibl
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.

Authors:  P Kaufmann-Kolle; J Drevs; M R Berger; J Kötting; N Marschner; C Unger; H Eibl
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  [Isolation of free-living amoebae from nasal mucosa of healthy individuals].

Authors:  R Michel; R Röhl; H Schneider
Journal:  Zentralbl Bakteriol Mikrobiol Hyg B       Date:  1982-05
View more
  41 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  In vitro amoebicidal activities of Satureja cuneifolia and Melissa officinalis on Acanthamoeba castellanii cysts and trophozoites.

Authors:  E Malatyali; B Tepe; S Degerli; S Berk
Journal:  Parasitol Res       Date:  2011-12-09       Impact factor: 2.289

3.  Amoebicidal activity of the rhizomes and aerial parts of Allium sivasicum on Entamoeba histolytica.

Authors:  S Degerli; S Berk; B Tepe; E Malatyali
Journal:  Parasitol Res       Date:  2012-01-04       Impact factor: 2.289

4.  Acanthamoebicidal activity of Fusarium sp. Tlau3, an endophytic fungus from Thunbergia laurifolia Lindl.

Authors:  Narumon Boonman; Suthep Wiyakrutta; Nongluksna Sriubolmas; Araya Dharmkrong-at Chusattayanond
Journal:  Parasitol Res       Date:  2008-07-17       Impact factor: 2.289

5.  Identification and distribution of Acanthamoeba species genotypes associated with nonkeratitis infections.

Authors:  Gregory C Booton; Govinda S Visvesvara; Thomas J Byers; Daryl J Kelly; Paul A Fuerst
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

6.  Tigecycline inhibits proliferation of Acanthamoeba castellanii.

Authors:  Bijay Kumar Jha; Incheol Seo; Hyun-Hee Kong; Seong-Il Suh; Min-Ho Suh; Won-Ki Baek
Journal:  Parasitol Res       Date:  2015-01-07       Impact factor: 2.289

Review 7.  Disseminated Acanthamoeba infection in a heart transplant recipient treated successfully with a miltefosine-containing regimen: Case report and review of the literature.

Authors:  Max N Brondfield; Michael J A Reid; Rachel L Rutishauser; Jennifer R Cope; Jevon Tang; Jana M Ritter; Almea Matanock; Ibne Ali; Sarah B Doernberg; Alexandra Hilts-Horeczko; Teresa DeMarco; Liviu Klein; Jennifer M Babik
Journal:  Transpl Infect Dis       Date:  2017-03-06       Impact factor: 2.228

8.  Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.

Authors:  José M Jiménez-López; Pablo Ríos-Marco; Carmen Marco; Josefa L Segovia; María P Carrasco
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

9.  In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.

Authors:  Anjan Debnath; Josefino B Tunac; Angélica Silva-Olivares; Silvia Galindo-Gómez; Mineko Shibayama; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

10.  Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine.

Authors:  Alexander C Aichelburg; Julia Walochnik; Ojan Assadian; Helmut Prosch; Andrea Steuer; Gedeon Perneczky; Govinda S Visvesvara; Horst Aspöck; Norbert Vetter
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.